Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 31 for:    "Transitional Cell Carcinoma" | "Atezolizumab"

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03737123
Recruitment Status : Recruiting
First Posted : November 9, 2018
Last Update Posted : October 8, 2019
Sponsor:
Collaborators:
Genentech, Inc.
Indiana University School of Medicine
Information provided by (Responsible Party):
Nabil Adra, Hoosier Cancer Research Network

Brief Summary:
This is a single arm phase II study assessing the activity of atezolizumab in combination with carboplatin + gemcitabine or docetaxel compared to historical controls of chemotherapy only in metastatic or recurrent urothelial carcinoma subjects. Subjects that received a PD 1 or PD-L1 inhibitor with no prior platinum chemotherapy for metastatic disease will be treated with atezolizumab + carboplatin + gemcitabine on trial. Subjects that received sequential or concurrent PD1/PDL1 inhibitor and carboplatin-based regimen will be treated with atezolizumab + docetaxel on trial.

Condition or disease Intervention/treatment Phase
Urothelial Carcinoma Drug: Carboplatin Drug: Gemcitabine Drug: Atezolizumab Drug: Docetaxel Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 33 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: HCRN GU17-295
Actual Study Start Date : December 19, 2018
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Chemotherapy and Atezolizumab
Subjects that received a PD 1 or PD-L1 inhibitor with no prior platinum chemotherapy for metastatic disease will be treated with atezolizumab + carboplatin + gemcitabine on trial. Subjects that received sequential or concurrent PD1/PDL1 inhibitor and carboplatin-based regimen will be treated with atezolizumab + docetaxel on trial.
Drug: Carboplatin
Carboplatin AUC 4 IV Day 1 of each 21 day cycle
Other Name: paraplatin

Drug: Gemcitabine
Gemcitabine 1,000 mg/m2 IV Day 1 and Day 8 of each 21 day cycle
Other Name: Gemzar

Drug: Atezolizumab
Atezolizumab 1,200 mg IV Day 1 of each 21 day cycle
Other Name: Tecentriq

Drug: Docetaxel
Docetaxel 75 mg/m2 IV Day 1 of each 21 day Cycle.
Other Name: Taxotere




Primary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: 18 months ]
    Evaluate PFS among patients to be treated with atezolizumab in combination with carboplatin + gemcitabine or docetaxel, who have cisplatin-ineligible metastatic urothelial carcinoma and who have progressed on prior PD-1 or PD-L1 inhibitor. PFS defined as duration from date of treatment start until progression according to RECIST 1.1 criteria, or death from any cause.


Secondary Outcome Measures :
  1. Assess adverse events [ Time Frame: 18 months ]
    Adverse events will be graded according to CTCAE 4.03

  2. Objective Response Rate (ORR) [ Time Frame: 18 months ]
    ORR using RECIST 1.1 and irRECIST defined as the proportion of all subjects with confirmed PR or CR according to RECIST 1.1 and irRECIST, from the start of treatment until disease progression/recurrence.

  3. Clinical benefit rate (CBR) [ Time Frame: 18 months ]
    CBR of treatment (defined by proportion of all subjects with stable disease for at least 3 months, partial response, or complete response) using RECIST 1.1 and irRECIST from the start of treatment until disease progression/recurrence

  4. PFS by irRECIST [ Time Frame: 18 months ]
    PFS defined as duration from date of treatment start until progression according to irRECIST criteria or death from any cause

  5. Overall Survival (OS) [ Time Frame: 18 months ]
    OS defined by the date of treatment start to date of death from any cause

  6. Progression Free Survival (PFS) [ Time Frame: 18 months ]
    Compare PFS compared to historical controls. PFS defined as duration from date of treatment start until progression according to RECIST 1.1 criteria, or death from any cause.

  7. Progression Free Survival (PFS) [ Time Frame: 18 months ]
    Evaluate PFS for atezolizumab + carboplatin and gemcitabine. PFS defined as duration from date of treatment start until progression according to RECIST 1.1 criteria, or death from any cause.

  8. Progression Free Survival (PFS) [ Time Frame: 18 months ]
    Evaluate PFS for atezolizumab + docetaxel. PFS defined as duration from date of treatment start until progression according to RECIST 1.1 criteria, or death from any cause.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
  • Age ≥ 18 years at the time of consent.
  • ECOG Performance Status of 0-2 within 28 days prior to registration.
  • Histological or cytological confirmed metastatic or unresectable locally advanced urothelial carcinoma (primary tumor: renal pelvis, ureters, urinary bladder, or urethra).
  • Patients with mixed histologies are eligible.
  • Cisplatin ineligible at the time of diagnosis with metastatic urothelial carcinoma based on consensus definition with any of the following criteria: ECOG PS 2, creatinine clearance < 60mL/min, CTCAE v4 grade ≥ 2 hearing loss, CTCAE v4 grade ≥ 2 peripheral neuropathy, New York Heart Association (NYHA) class ≥ 3 heart failure.
  • Measurable disease according to RECIST 1.1 within 28 days prior to registration.
  • Must have had progressive metastatic disease after previous treatment with PD-1 or PD-L1 inhibitor (in the adjuvant or metastatic setting). Treatment regimen will be determined based on prior treatment:

    • PD1 or PDL1 inhibitor with no prior platinum chemotherapy for metastatic disease. These patients should be treated with atezolizumab + carboplatin + gemcitabine on trial.
    • Sequential or concurrent PD1/PDL1 inhibitor and carboplatin-based regimen. These patients should be treated with atezolizumab + docetaxel on trial.
  • Most recent therapy does not have to have been a checkpoint inhibitor. Intercurrent treatment is acceptable if subjects meet all other inclusion criteria.
  • A subject with prior brain metastasis may be considered if they have completed their treatment for brain metastasis at least 4 weeks prior to study registration, have been off of corticosteroids for ≥ 2 weeks, and are asymptomatic.
  • Previous neoadjuvant or adjuvant chemotherapy that was completed 6 months prior to study enrollment is allowed.
  • REQUIRED archival tumor tissue (prior to treatment with single agent PD-1 or PD-L1 inhibitor) must be identified prior to registration and obtained during the screening period. Confirmation of acquisition should occur prior to C1D1 treatment. Unavailability of tissue will render the subject ineligible for study. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient. Sample requirement is FFPE block + 1 H&E stained slide or 25 unstained slides + 1 H&E stained slide.
  • Demonstrate adequate organ function as defined in the table below. All screening labs to be obtained within 28 days prior to registration.

    • White blood cell (WBC) ≥ 2 k/mm3
    • Absolute Neutrophil Count (ANC) ≥ 1.5 K/mm3
    • Hemoglobin (Hgb) ≥ 9 g/dL
    • Platelet >100k
    • Estimated creatinine clearance ≥ 30 mL/min
    • Bilirubin 1.5 ≤ (ULN)
    • Aspartate aminotransferase (AST) ≤ 1.5 × ULN
    • Alanine aminotransferase (ALT) ≤ 1.5 × ULN
    • International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) ≤ 2 × ULN (Note: This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose)
  • Females of childbearing potential (FOCBP) must have a negative serum pregnancy test within 28 days prior to registration. These women must also have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of atezolizumab then every 6 weeks thereafter. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is post-menopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 62 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.
  • Females of childbearing potential and males must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 150 days (5 months) after treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method.
  • Men who are sexually active with FOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving atezolizumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 150 days (5 months) after the last dose of investigational product.
  • As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.

Exclusion Criteria:

  • Previous autoimmune complication from PD-1 or PD-L1 inhibitor requiring permanent discontinuation of therapy.
  • Previous permanent discontinuation from PD-1 or PD-L1 inhibitor due to an adverse event (patients who had temporary holds or discontinuation of PD-1 or PD-L1 inhibitor and then re-treated are eligible).
  • Any serious or uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy.
  • Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
  • 5. Has a known additional malignancy that is progressing or required treatment ≤ 48 months of study registration. Exceptions: include malignancies with negligible risk of metastasis or death treated with expected curative outcome or undergoing surveillance per investigator's discretion (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, ductal carcinoma in situ treated surgically with curative intent, or very low risk or low risk prostate cancer per NCCN guidelines).
  • Active central nervous system (CNS) metastases. Subjects with brain metastases are eligible if metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression within 28 days prior to the first dose of atezolizumab administration. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration.
  • Treatment with any investigational drug within 30 days prior to registration.
  • Subjects with an active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids/immunosuppressive medications EXCEPT for syndromes which would not be expected to recur in the absence of an external trigger. (Subjects with vitiligo, autoimmune thyroiditis, or type I diabetes mellitus are permitted to enroll.).
  • As there is potential for hepatic toxicity with atezolizumab, drugs with a predisposition to hepatoxicity should be used with caution in subjects treated with atezolizumab-containing regimen.
  • Subjects should be excluded if they have known history of testing positive for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection. Testing is not required.
  • Subjects should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). Testing is not required.
  • History of allergy to atezolizumab or respective chemotherapy regimen (carboplatin + gemcitabine or docetaxel).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03737123


Contacts
Layout table for location contacts
Contact: Nabil Adra, MD 317-948-6942 nadra@iu.edu
Contact: Robyn Lillie 317-634-5842 ext 60 rlillie@hoosiercancer.org

Locations
Layout table for location information
United States, Indiana
Indiana University Melvin and Bren Simon Cancer Center Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Nabil Adra, MD    317-948-6942    nadra@iu.edu   
Contact: Yvonne Lafary    317-278-5613    ylafary@iu.edu   
Principal Investigator: Nabil Adra, MD         
Sub-Investigator: Costantine Albany, MD         
Sub-Investigator: Roberto Pili, MD         
United States, Nebraska
Nebraska Methodist Hosptial Recruiting
Omaha, Nebraska, United States, 68114
Contact: Craig Ryan    402-354-7938    craig.ryan@nmhs.org   
Principal Investigator: Ralph Hauke, MD         
Sponsors and Collaborators
Nabil Adra
Genentech, Inc.
Indiana University School of Medicine
Investigators
Layout table for investigator information
Principal Investigator: Nabil Adra, MD Indiana University Melvin and Bren Simon Cancer Center

Layout table for additonal information
Responsible Party: Nabil Adra, Sponsor-Investigator, Hoosier Cancer Research Network
ClinicalTrials.gov Identifier: NCT03737123     History of Changes
Other Study ID Numbers: GU17-295
First Posted: November 9, 2018    Key Record Dates
Last Update Posted: October 8, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Atezolizumab
Carcinoma
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Gemcitabine
Cisplatin
Carboplatin
Docetaxel
Antibodies, Monoclonal
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators